---
id: isth-anticoagulation-reversal-2024
title: "ISTH 2024 Guidance on Anticoagulation Reversal and Management of Bleeding"
short_title: "ISTH Anticoag Reversal 2024"

organization: International Society on Thrombosis and Haemostasis
collaborators: null
country: Global
url: https://www.isth.org/page/Guidelines
doi: null
pmid: null
open_access: true

specialty: hematology
guideline_type: clinical-practice
evidence_system: ISTH
conditions:
  - anticoagulation reversal
  - major bleeding
  - DOAC bleeding
tags:
  - idarucizumab
  - andexanet alfa
  - vitamin K
  - PCC
  - warfarin reversal

publication_date: 2024-04-01
previous_version_date: 2019-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 ISTH guidance on the management and reversal of anticoagulation in patients with major bleeding or requiring urgent surgery.

## Key Recommendations

### General Principles
- Stop anticoagulant.
- Supportive care: IV access, blood products, hemodynamic support.
- Identify and control bleeding source (surgical, endoscopic, interventional).

### Warfarin (Vitamin K Antagonist) Reversal
- **Vitamin K (10 mg IV)**: Slow reversal (6-24 hours).
- **4-Factor Prothrombin Complex Concentrate (4F-PCC)**: Rapid reversal. INR-based dosing (e.g., 25-50 units/kg). First-line for major bleeding or urgent surgery.
- Fresh frozen plasma (FFP): Less preferred due to volume, infection risk, and slower reversal.
- Target INR <1.5.

### Direct Oral Anticoagulant (DOAC) Reversal

#### Dabigatran (Direct Thrombin Inhibitor)
- **Idarucizumab (Praxbind)**: Specific reversal agent. Dose: 5 g IV.
- Dialysis can remove dabigatran if idarucizumab unavailable.

#### Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban)
- **Andexanet Alfa (Andexxa)**: Specific reversal agent for rivaroxaban and apixaban. Approved but costly and limited availability.
- **4F-PCC (25-50 units/kg)**: Can be used if andexanet is unavailable. Provides hemostatic support, though not a true reversal.

### Activated Charcoal
- If recent oral DOAC ingestion (<2-4 hours), may reduce absorption.

### Minor Bleeding
- Often managed with supportive care and holding anticoagulation. Specific reversal agents not typically needed.

### Anticoagulation Resumption
- Weigh thrombotic vs. bleeding risk. Generally resume when hemostasis achieved and bleeding source controlled.
